SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study

NCT ID: NCT04776434

Last Updated: 2025-09-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

723 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-08

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Open label, real-world, prospective, multi-center, single arm, post-market surveillance study of the SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Open label, real-world, prospective, multi-center, single arm, post-market surveillance study of the SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB).

This study will capture data from the use of the SELUTION SLR according to its approved labelling. Each indication for use will have a specific data sets in addition to generic data sets that are common across all indications.

Patients will be followed for 5 years post-procedure to obtain safety and efficacy data. A health economic analysis will be made comparing data between countries within the study and to published data for existing treatment options. Generic and disease specific Patient Reported Outcome Measures (PROMs) will be used to measure the impact of the intervention on the overall health status of patients.

Imaging data collection for patients whose standard of care includes imaging follow-up will be captured and analysed.

Data will be collected from any subject who receives a CE marked device for treatment of a peripheral (i.e. non-cardiovascular) vascular lesion.

Data analysis will be stratified by lesion location.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SELUTION SLR™ DEB

Med Alliance SELUTION SLR™ 018 DEB Sirolimus Eluting Balloon Catheter.

Group Type EXPERIMENTAL

SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB)

Intervention Type DEVICE

This study will capture data from the use of the SELUTION SLR according to its approved labelling.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB)

This study will capture data from the use of the SELUTION SLR according to its approved labelling.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject age is ≥ 18 years
* Subject is able and willing to provide informed consent
* Subject is suitable for treatment with a MedAlliance SELUTION SLR DEB according to the current Instruction for use.

Exclusion Criteria

* In the opinion of the treating investigator the subject has a life expectancy of less than 12 months
* In the opinion of the treating investigator the subject is unlikely to comply with the study follow-up regime
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

M.A. Med Alliance S.A.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Italiano La Plata

La Plata, , Argentina

Site Status

Klinikum Hochsauerland

Arnsberg, , Germany

Site Status

Universitätsklinikum Freiburg

Bad Krozingen, , Germany

Site Status

Krankenhaus Buchholz

Buchholz, , Germany

Site Status

Universitätsklinikum Essen

Essen, , Germany

Site Status

DIAKO Krankenhaus

Flensburg, , Germany

Site Status

Medizinisches Versorgungszentrum

Hamburg, , Germany

Site Status

Universitätsklinikum Heidelberg

Heidelberg, , Germany

Site Status

SRH Klinikum Karlsbad - Langensteinbach

Langensteinbach, , Germany

Site Status

LMU Klinikum Campus Großhadern

München, , Germany

Site Status

Universitätsklinikum Tübingen

Tübingen, , Germany

Site Status

Grn Klinik Weinheim

Weinheim, , Germany

Site Status

Universitätsklinikum Würzburg

Würzburg, , Germany

Site Status

Athens Medical Center

Athens, , Greece

Site Status

Attikon University Hospital

Athens, , Greece

Site Status

General University Hospital of Patras

Pátrai, , Greece

Site Status

Elisabeth - TweeSteden Ziekenhuis

Tilburg, , Netherlands

Site Status

National University Hospital Singapore (NUHS)

Singapore, , Singapore

Site Status

Trnava University Hospital

Trnava, , Slovakia

Site Status

Kantonsspital Aarau

Aarau, , Switzerland

Site Status

Hôpitaux Universitaires de Genève (HUG)

Geneva, , Switzerland

Site Status

Luzerner Kantonsspital

Lucerne, , Switzerland

Site Status

Frimley Park Hospital

Frimley, , United Kingdom

Site Status

University Hospitals of Leicester NHS Trust

Leicester, , United Kingdom

Site Status

Barts Health NHS Trust (ROYAL HOSPITAL LONDON)

London, , United Kingdom

Site Status

Guy's & St Thomas Hospital

London, , United Kingdom

Site Status

East Surrey Hospital

Redhill, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Argentina Germany Greece Netherlands Singapore Slovakia Switzerland United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

S2020-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

AcoArt Ⅰ / SFA China
NCT01850056 COMPLETED NA
Zilver® PTX® in China
NCT02171962 COMPLETED NA
Stellarex Vascular E-Registry
NCT02769273 COMPLETED